Journal of Crohn's & colitis
Cure8 research brief
Why This Matters
The study evaluates how well first-line 5-ASA therapy achieves modern treatment targets (endoscopic, histologic, and biomarker remission) in real-world UC patients who are clinically in remission. Patients and clinicians may care because objective healing does not always match symptom resolution.
Who Should Pay Attention
Adult patients with mild-to-moderate ulcerative colitis on 5-ASA, gastroenterologists and IBD clinicians, and clinical researchers studying real-world outcomes and biomarkers in UC.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This cross-sectional phase 4 study enrolled 198 UC patients in clinical remission on 5-ASA only (oral, rectal, or combination) for at least 6 months and excluded those on corticosteroids, immunomodulators, or advanced therapies.
Investigators assessed multiple remission definitions: patient-reported outcomes (PRO-2), endoscopic scores (MES, UCEIS), histology (Geboes), and fecal calprotectin. While 78% had biological remission, 87% had endoscopic remission and 80% histological remission, only 24% met a composite deep remission definition largely because urgency persisted.
Practical takeaways: The results support that 5-ASA remains an effective treatment for achieving objective mucosal and biomarker remission in many patients with mild-to-moderate UC.
However, persistent symptoms such as urgency can remain despite mucosal healing, highlighting the need for clinicians to assess and address residual symptoms even when endoscopy and biomarkers look good.
Keep In Mind
This classification is grounded in the article abstract (structured content depth: abstract). The study is cross-sectional and reports remission rates at a single timepoint among patients already in clinical remission on 5-ASA; it does not provide longitudinal treatment comparisons or causal conclusions.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationJournal of Crohn's & colitis
AuthorsReenaers C, Lambrecht G, Pouillon L +15 more
Study typeMulticenter study, journal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedAug 1, 2026, 12:00 AM
Content availableJournal abstract
Funding disclosed by the source: Ferring
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Underevaluation of bowel urgency in clinical care: patient experiences and outcomes in ulcerative colitis: a retrospective cohort study
Bowel urgency is a common symptom that may predict higher risk of treatment escalation, hospitalization, or surgery in UC even when bleeding and stool frequency look controlled. Better assessment of urgency in clinic...
Understanding role of microbiota in Crohn's disease, ulcerative colitis
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...
A Real-World Study of Upadacitinib in Anti-TNF Refractory Crohn's Disease - Dove Medical Press
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.